Boehringer Ingelheim Expanded Variant Bio Partnership
The pharmaceutical company deepened its cardiovascular research collaboration to discover new drug targets.
Updated on Sept. 23, 2026 in Heart Disease
Live Poll
Do you believe partnerships between AI companies and drug makers will lead to better medical treatments?
Boehringer Ingelheim has expanded its collaboration with Seattle-based Variant Bio to include cardiovascular disease research. The agreement adds more than $250 million in potential milestone and license payments to the partnership.
Why it matters
The collaboration aims to address the global challenge of interconnected cardiovascular and kidney diseases by identifying genetically supported drug targets. By leveraging genomic data, the partners hope to accelerate the development of effective new treatments.
The expanded agreement adds over $250 million in potential milestone and license payments. This follows an initial January 2026 partnership between the two companies valued at $120 million.
The players
Boehringer Ingelheim
This German-based pharmaceutical company is a global leader in the research and development of human and animal health medications.
Variant Bio
Headquartered in Seattle, this biotechnology firm utilizes a specialized AI-powered Inference platform to conduct human genomic target discovery.
Novo Nordisk
A global healthcare company known for its focus on diabetes and obesity care that entered its own research agreement with Variant Bio in 2025.
The details
Boehringer Ingelheim will utilize Variant Bio's AI-powered Inference platform, which integrates genomic and multiomic data to validate potential targets. This effort complements Boehringer Ingelheim's existing cardiovascular portfolio, which includes market-established drugs like Jardiance, Pradaxa, and Twynsta.
Timeline
January 2025: Novo Nordisk entered a separate research pact with Variant Bio.
January 2026: Boehringer Ingelheim and Variant Bio formed their initial $120 million partnership.
September 23, 2026: The companies announced the expansion of their collaboration into cardiovascular disease.
The Big Picture
This move extends the use of the Inference platform developed by Variant Bio to identify new drug targets for cardiovascular disease. It follows the pattern set by the platform's initial deployment in 2026 to discover and validate therapeutic targets using genomic data.
The development of new targets may eventually lead to novel pharmaceutical treatments for cardiovascular and kidney conditions. This research effort focuses on long-term clinical advancements rather than immediate changes to current patient medication routines.
The takeaway
Partnerships between AI-driven biotech firms and established pharmaceutical companies are becoming a standard approach for identifying complex genetic targets. These collaborations highlight a shifting reliance on multiomic data to address interconnected chronic health challenges.
Further reading
For more information on current treatment trends, visit our Heart Disease section.
Live Poll
Do you believe partnerships between AI companies and drug makers will lead to better medical treatments?
